CD86 and neoplasm: Immunofluorescence assays corroborated these findings, revealing a reduced percentage of CD86+ M1 macrophages and an increased percentage of CD163+ M2 macrophages and CD4+Foxp3+ Treg cells in mutated tumor tissues (Figure 4J).